Letter Regarding Editorial by Samuel Zagarella

Affiliations

¹ The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
² Unit of Melanoma, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
³ Netherlands Cancer Institute, Amsterdam, Netherlands.
⁴ University of California Los Angeles, Los Angeles, CA.
⁵ Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA.
⁶ Peter MacCallum Cancer Centre, Melbourne, Australia.
⁷ Division of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.
⁸ Cutaneous Oncology Program, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
⁹ Oregon Health Science University, Portland, OR.
¹⁰ Hospital of the University of Pennsylvania, Philadelphia, PA.
¹¹ California Pacific Medical Center, San Francisco, CA.
¹² Norfolk and Norwich University Hospital, Norwich, United Kingdom.
¹³ Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
¹⁴ Fondazione IRCCS Policlinico San Matteo, Divisione di Dermatologia, Pavia, Italy.
¹⁵ Department of Surgery, Professor of Surgery, Geisel School of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
¹⁶ Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL.
¹⁷ Department of Oncological Sciences, University of South Florida Morsani School of Medicine, Tampa, FL.

Comment

Mark B Faries et al. Am J Dermatopathol. 2021.

. 2021 Jul 1;43(7):539-541.

doi: 10.1097/DAD.0000000000001857.

¹ The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
² Unit of Melanoma, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
³ Netherlands Cancer Institute, Amsterdam, Netherlands.
⁴ University of California Los Angeles, Los Angeles, CA.
⁵ Winship Cancer Institute of Emory University School of Medicine, Atlanta, GA.
⁶ Peter MacCallum Cancer Centre, Melbourne, Australia.
⁷ Division of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.
⁸ Cutaneous Oncology Program, The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA.
⁹ Oregon Health Science University, Portland, OR.
¹⁰ Hospital of the University of Pennsylvania, Philadelphia, PA.
¹¹ California Pacific Medical Center, San Francisco, CA.
¹² Norfolk and Norwich University Hospital, Norwich, United Kingdom.
¹³ Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
¹⁴ Fondazione IRCCS Policlinico San Matteo, Divisione di Dermatologia, Pavia, Italy.
¹⁵ Department of Surgery, Professor of Surgery, Geisel School of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
¹⁶ Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL.
¹⁷ Department of Oncological Sciences, University of South Florida Morsani School of Medicine, Tampa, FL.

No abstract available

Conflict of interest statement

The authors declare no conflicts of interest.

In Response.
Zagarella S. Zagarella S. Am J Dermatopathol. 2021 Jul 1;43(7):541-542. doi: 10.1097/DAD.0000000000001828. Am J Dermatopathol. 2021. PMID: 33055538 No abstract available.

Sentinel Lymph Node Biopsy Still Provides No Benefits for Patients With Melanoma.
Zagarella S. Zagarella S. Am J Dermatopathol. 2020 Jul;42(7):481-483. doi: 10.1097/DAD.0000000000001656. Am J Dermatopathol. 2020. PMID: 32310861 No abstract available.

1. Zagarella S. Sentinel lymph node biopsy still provides No benefits for patients with melanoma. Am J Dermatopathol. 2020;42:481–483.
1. Pournamdari AB, Tkachenko E, Barbieri J, et al. A state-of-the-art review highlighting medical overuse in dermatology, 2017-2018: a systematic review. JAMA Dermatol. 2019.
1. Mitra A, Conway C, Walker C, et al. Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer. 2010;103:1229–1236.
1. Freeman SR, Gibbs BB, Brodland DG, et al. Prognostic value of sentinel lymph node biopsy compared with that of Breslow thickness: implications for informed consent in patients with invasive melanoma. Dermatol Surg. 2013;39:1800–1812.
1. Karakousis GC, Gimotty PA, Czerniecki BJ, et al. Regional nodal metastatic disease is the strongest predictor of survival in patients with thin vertical growth phase melanomas: a case for SLN Staging biopsy in these patients. Ann Surg Oncol. 2007;14:1596–1603.